TrialTransplant international : official journal of the European Society for Organ Transplantation2026
Bortezomib in combination with standard-of-care for late active antibody-mediated rejection with de novo donor-specific antibodies after kidney transplantation: a multicenter randomized trial.
Renaud Snanoudj et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.